Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 17/20 | 0.60 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | LYN | P07948 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
| ▸ | ACVR2B | Q13705 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2193474 | 0.84 | BRAF (0.79) | BRAFEGFRLCKLYNTGFBR1 | |
| SCHEMBL12350547 | 0.81 | BRAF (0.80) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL18636551 | 0.80 | BRAF (0.69) | BRAFEGFRLCKLYNTGFBR1 | |
| SCHEMBL12350556 | 0.77 | BRAF (0.73) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL2193377 | 0.76 | BRAF (0.77) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL2192723 | 0.75 | BRAF (1.00) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL2193018 | 0.75 | BRAF (0.59) | BRAFEGFRLCKLYNTGFBR1 | |
| SCHEMBL2194663 | 0.75 | BRAF (0.56) | BRAFEGFRLCKLYNTGFBR1 | |
| SCHEMBL12349996 | 0.74 | BRAF (0.80) | BRAFLCKLYNTGFBR1BTK | |
| SCHEMBL12350428 | 0.73 | BRAF (0.75) | BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9233956-B2 | Benzene sulfonamide thiazole and oxazole compounds | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2014-03-20 | — | — | US | disclosed |
| US-8642759-B2 | Benzene sulfonamide thiazole and oxazole compounds | GLAXOSMITHKLINE LLC (US) | 2014-02-04 | — | — | US | disclosed |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | GLAXOSMITHKLINE LLC (US) | 2013-06-06 | — | — | US | disclosed |
| US-8415345-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo SmithKline LLC (US) | 2013-04-09 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EGFR 2172/4885LCK 598/4885 |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EGFR 2172/4885LCK 598/4885 |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EGFR 2172/4885LCK 598/4885 |
| US-20140080851-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EGFR 2172/4885LCK 598/4885 |
| US-20130144055-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EGFR 2172/4885LCK 598/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EGFR 2172/4885LCK 598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.